Why the study?
Does preoperative antiplatelet therapy increase bleeding and transfusion in ATAAD patients misdiagnosed as ACS undergoing emergency operation?
Does preoperative antiplatelet therapy increase bleeding and transfusion in ATAAD patients misdiagnosed as ACS undergoing emergency operation?
Preoperative antiplatelet therapy in ATAAD misdiagnosed as ACS increases bleeding and transfusion risks during emergency surgery, highlighting the need to carefully balance rupture and hemorrhage risks when timing operations.
Answers are grounded in this paper and cite their sources.
Requires careful ACS-ATAAD differentiation before antiplatelet use; leaves open optimal timing and management strategies.
ATAAD misdiagnosed as ACS is not rare, and APT will increase the risk of bleeding in ATAAD patients. The decision of operation time relies on considering the balance between the rupture risk of aortic dissection and the hemorrhage risk of APT. The emergency operation for these patients will increase bleeding and transfusion.
No takes yet. Share an insight, caveat, or question.
Xue et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: